Shankar Hariharan - 19 Sep 2024 Form 4 Insider Report for Scienture Holdings, Inc. (SCNX)

Role: Co-CEO & Chairman, Director, 10%+ Owner
Signature: /s/ Kate L. Bechen, as attorney-in-fact for Shankar Hariharan
Issuer symbol: SCNX
Transactions as of: 19 Sep 2024
Net transactions value: $0
Form type: 4
Filing time: 12 Mar 2026, 21:32:55 UTC
Previous filing: 05 Aug 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Shankar Hariharan	Co-CEO & Chairman, Director, 10%+ Owner	C/O SCIENTURE HOLDINGS, INC., 20 AUSTIN BLVD., COMMACK	/s/ Kate L. Bechen, as attorney-in-fact for Shankar Hariharan	12 Mar 2026	0002031316

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SCNX	Common Stock, par value $0.00001	Conversion of derivative security		+1,916,816	+2341%		1,998,679	19 Sep 2024	Direct	F1
transaction	SCNX	Common Stock, par value $0.00001	Conversion of derivative security		+356,480	+2342%		371,704	19 Sep 2024	By Spouse	F1
transaction	SCNX	Common Stock, par value $0.00001	Other		-30,000	-1.5%	$0.000000^*	1,968,679	10 Mar 2025	Direct	F2
transaction	SCNX	Common Stock, par value $0.00001	Award		+750,000	+38%	$0.000000^*	2,718,679	14 Apr 2025	Direct	F3
transaction	SCNX	Common Stock, par value $0.00001	Award		+300,000	+11%	$0.000000^*	3,018,679	01 Oct 2025	Direct	F4
transaction	SCNX	Common Stock, par value $0.00001	Award		+500,000	+17%	$0.000000^*	3,518,679	20 Feb 2026	Direct	F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SCNX	Series X Non-Voting Convertible Preferred Stock	Conversion of derivative security		-1,916,816	-100%	$0.000000^*	0	19 Sep 2024	Common Stock, par value $0.00001	1,916,816		Direct	F1
transaction	SCNX	Series X Non-Voting Convertible Preferred Stock	Conversion of derivative security		-356,480	-100%	$0.000000^*	0	19 Sep 2024	Common Stock, par value $0.00001	356,480		By spouse	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares of the Series X Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the "Series X Preferred Stock"), of Scienture Holdings, Inc. (the "Issuer"), formerly known as TRxADE HEALTH, INC., automatically converted on a one-for-one basis into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on the twentieth calendar day following the Issuer's mailing of an information statement on Schedule 14C in connection with the closing of the Issuer's previously announced acquisition of Scienture, Inc. on July 25, 2024 pursuant to an Agreement and Plan of Merger. The Series X Preferred Stock had no expiration date.
F2	These shares of Common Stock were transferred by Dr. Shankar Hariharan to a designee of NVK Finance, LLC (the "Lender") as consideration for the Lender's consent to certain transactions contemplated by that certain First Amendment to Loan and Security Agreement, dated November 22, 2024, entered into by the Issuer, the Lender, Dr. Hariharan, and certain other parties thereto.
F3	These shares of restricted Common Stock ("Restricted Shares") vest in two equal annual installments beginning on April 14, 2026.
F4	These Restricted Shares vest in two equal annual installments beginning on October 1, 2026.
F5	On February 20, 2026, the Compensation Committee of the Issuer's Board of Directors approved the award of these Restricted Shares as a discretionary stock bonus for performance in 2025. The Restricted Shares will be issued in three tranches of 166,666 shares on June 1, 2026, 166,667 shares on September 1, 2026, and 166,667 shares on December 1, 2026. Each tranche of Restricted Shares will vest three years following its respective issuance date.